血小板输注无效原因及对策研究进展
摘要
<正>血小板输注被广泛应用于治疗各种血小板减少出血性疾病、预防血小板计数明显减少引起的自发性出血,是现今成分输血的重要组成部分。但是临床上很多患者在输入足量血小板后,血小板计数并未明显增加、出血症状也不能得到控制,输注的同时大部分患者还会出现发热、过敏等不良反应,这被定义为血小板输注无效(PTR)。PTR发生原因包括非免疫因素和免疫因素2个方面,解决对策包括掌握输注指
引文
[1]REFAAI M A,CARTER J,HENRICHS K F,et al.Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and-B[J].Transfusion,2013,53(2):382-393.
[2]李玉梅,徐恒仕,王志良.HPA基因多态性及其等位基因对血小板输注效果的影响[J].中国输血杂志,2017,30(7):744-747.
[3]赵毓宏,曹建平,邓永乐,等.HPA1-6,15基因遗传多态性在血小板输注中的应用研究[J].临床血液学杂志(输血与检验),2017,30(4):587-590.
[4]TRIULZI D J,KLEINMAN S,KAKAIYA R M,et al.The effect of previous pregnancy and transfusion on HLAalloimmunization in blood donors:implications for a transfusion-related acute lung injury risk reduction strategy[J].Transfusion,2009,49(9):1825-1835.
[5]RAMOS-ARELLANO L E,MU?OZ-VALLE J F,DELA CRUZ-MOSSO U,et al.Circulating CD36and oxLDL levels are associated with cardiovascular risk factors in young subjects[J].BMC Cardiovasc Disord,2014,28(14):54-59.
[6]KUIJPERS M J,DEWITT S,NERGIZ-UNAL R A,et al.Supporting roles of platelet thrombospondin-1and CD36in thrombus formation on collagen[J].Arterioscler Thromb Vasc Biol,2014,34(6):1187-1192.
[7]SAW C L,SZYKOLUK H,CURTIS B R,et al.Two cases of platelet transfusion refractoriness associated with anti-CD36[J].Transfusion,2010,50(12):2638-2642.
[8]XU X,YE X,XIA W,et al.Studies on CD36deficiency in south China:two cases demonstrating the clinical impact of anti-CD36antibodies[J].Thromb Haemost,2013,110(6):1199-1206.
[9]庄云龙,段志敏,陈蓉,等.江苏地区汉族人群血小板CD36抗原表达差异的研究[J].中国输血杂志,2017,30(1):19-21.
[10]杨九一,顾健.药源性血小板减少症机制研究进展[J].中国医院药学杂志,2013,33(22):1874-1877.
[11]石洁,段志倩,郑建勇.单采血小板保存期内各项生化标志物的动态变化[J].临床输血与检验,2017,19(4):325-327.
[12]陈涛.重症感染合并血小板减少症的影响因素及其相关性分析[J].重庆医学,2016,45(1):51-52.
[13]HOD E,SCHWARTZ J.Platelet transfusion refractoriness[J].Br J Haematol,2008,142(3):348-360.
[14]刘洋,崔若帅,马春娅,等.血液病患者血小板输注效果对比及无效原因分析[J].国际检验医学杂志,2017,38(13):1836-1838.
[15]杜春红,徐佩琦,李红学.血小板输注无效相关因素的研究进展[J].临床输血与检验,2016,18(1):86-89.
[16]DEZERN A E,PETRI M,DRACHMAN D B,et al.Highdose cyclophosphamide without stem cell rescue in 207patients with aplastic anemia and other autoimmune diseases[J].Medicine(Baltimore),2011,90(2):89-98.
[17]QIAO J,WU Y,LIU Y,et al.Busulfan triggers intrinsic mitochondrial-dependent platelet apoptosis Independent of platelet activation[J].Biol Blood Marrow Transplant,2016,22(9):1565-1572.
[18]曹曰针,张琦,王苑,等.影响患者血小板输注效果的原因分析[J].中国输血杂志,2014,27(6):578-580.
[19]王卓,王修银,黄桢,等.临床血小板输注效果差异性研究[J].实验与检验医学,2016,34(4):528-529.
[20]SOLVES P,SANZ J,FREIRIA C,et al.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation[J].Ann Hematol,2018,97(1):161-167.
[21]周燕,李丽兰,钟周琳,等.造血干细胞移植术后抗-CD36抗体介导的血小板输注无效症和相关病例的实验研究[J].中国实验血液学杂志,2018,26(2):541-546.
[22]杨丽云,吴承高,刘威,等.冰冻单采血小板与新鲜单采血小板临床应用效果评价[J].中国输血杂志,2017,30(7):730-733.
[23]许飞,贺晨峰,曹锁春,等.常州地区单采血小板捐献者HLA抗原分布情况[J].临床血液学杂志(输血与检验),2018,31(2):294-296.
[24]傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[25]黎海燕,周燕,申卫东.CD36抗原缺失与血小板输注[J].中国实验血液学杂志,2016,24(3):934-938.
[2]李玉梅,徐恒仕,王志良.HPA基因多态性及其等位基因对血小板输注效果的影响[J].中国输血杂志,2017,30(7):744-747.
[3]赵毓宏,曹建平,邓永乐,等.HPA1-6,15基因遗传多态性在血小板输注中的应用研究[J].临床血液学杂志(输血与检验),2017,30(4):587-590.
[4]TRIULZI D J,KLEINMAN S,KAKAIYA R M,et al.The effect of previous pregnancy and transfusion on HLAalloimmunization in blood donors:implications for a transfusion-related acute lung injury risk reduction strategy[J].Transfusion,2009,49(9):1825-1835.
[5]RAMOS-ARELLANO L E,MU?OZ-VALLE J F,DELA CRUZ-MOSSO U,et al.Circulating CD36and oxLDL levels are associated with cardiovascular risk factors in young subjects[J].BMC Cardiovasc Disord,2014,28(14):54-59.
[6]KUIJPERS M J,DEWITT S,NERGIZ-UNAL R A,et al.Supporting roles of platelet thrombospondin-1and CD36in thrombus formation on collagen[J].Arterioscler Thromb Vasc Biol,2014,34(6):1187-1192.
[7]SAW C L,SZYKOLUK H,CURTIS B R,et al.Two cases of platelet transfusion refractoriness associated with anti-CD36[J].Transfusion,2010,50(12):2638-2642.
[8]XU X,YE X,XIA W,et al.Studies on CD36deficiency in south China:two cases demonstrating the clinical impact of anti-CD36antibodies[J].Thromb Haemost,2013,110(6):1199-1206.
[9]庄云龙,段志敏,陈蓉,等.江苏地区汉族人群血小板CD36抗原表达差异的研究[J].中国输血杂志,2017,30(1):19-21.
[10]杨九一,顾健.药源性血小板减少症机制研究进展[J].中国医院药学杂志,2013,33(22):1874-1877.
[11]石洁,段志倩,郑建勇.单采血小板保存期内各项生化标志物的动态变化[J].临床输血与检验,2017,19(4):325-327.
[12]陈涛.重症感染合并血小板减少症的影响因素及其相关性分析[J].重庆医学,2016,45(1):51-52.
[13]HOD E,SCHWARTZ J.Platelet transfusion refractoriness[J].Br J Haematol,2008,142(3):348-360.
[14]刘洋,崔若帅,马春娅,等.血液病患者血小板输注效果对比及无效原因分析[J].国际检验医学杂志,2017,38(13):1836-1838.
[15]杜春红,徐佩琦,李红学.血小板输注无效相关因素的研究进展[J].临床输血与检验,2016,18(1):86-89.
[16]DEZERN A E,PETRI M,DRACHMAN D B,et al.Highdose cyclophosphamide without stem cell rescue in 207patients with aplastic anemia and other autoimmune diseases[J].Medicine(Baltimore),2011,90(2):89-98.
[17]QIAO J,WU Y,LIU Y,et al.Busulfan triggers intrinsic mitochondrial-dependent platelet apoptosis Independent of platelet activation[J].Biol Blood Marrow Transplant,2016,22(9):1565-1572.
[18]曹曰针,张琦,王苑,等.影响患者血小板输注效果的原因分析[J].中国输血杂志,2014,27(6):578-580.
[19]王卓,王修银,黄桢,等.临床血小板输注效果差异性研究[J].实验与检验医学,2016,34(4):528-529.
[20]SOLVES P,SANZ J,FREIRIA C,et al.Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation[J].Ann Hematol,2018,97(1):161-167.
[21]周燕,李丽兰,钟周琳,等.造血干细胞移植术后抗-CD36抗体介导的血小板输注无效症和相关病例的实验研究[J].中国实验血液学杂志,2018,26(2):541-546.
[22]杨丽云,吴承高,刘威,等.冰冻单采血小板与新鲜单采血小板临床应用效果评价[J].中国输血杂志,2017,30(7):730-733.
[23]许飞,贺晨峰,曹锁春,等.常州地区单采血小板捐献者HLA抗原分布情况[J].临床血液学杂志(输血与检验),2018,31(2):294-296.
[24]傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[25]黎海燕,周燕,申卫东.CD36抗原缺失与血小板输注[J].中国实验血液学杂志,2016,24(3):934-938.